Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03840343 · ClinicalTrials.gov registry record · Phase 1
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03840343: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT03840343 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03840343, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The Researchers will assess the safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose (fat) tissue-derived mesenchymal stem/stromal cells (MSC) in patients with progressive diabetic kidney disease (DKD).
Primary Outcome
The number of Adverse Events associated with MSC intervention per treatment arm
Interventions
- BIOLOGICAL Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose
- BIOLOGICAL Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-10-23 |
| Est. Completion | 2020-08-04 |
| Phase | Phase 1 |
Why NCT03840343 stopped before completion
NCT03840343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose is the first listed.
NCT03840343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03840343 about?
NCT03840343 is a clinical study titled "Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease". The Researchers will assess the safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose (fat) tissue-derived mesenchymal stem/stromal cells (MSC) in patients with progressive diabetic kidney disease (DKD).
What is the current status of trial NCT03840343?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-10-23. Estimated completion is 2020-08-04.
What interventions are being tested in trial NCT03840343?
The interventions under investigation include: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose (BIOLOGICAL), Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT03840343?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03840343's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI